The Brazilian Journal of Nursing (Revista Brasileira de Enfermagem – REBEn), created in 1932, is the official publishing body of the Brazilian Nursing Association (ABEn - Associação Brasileira de Enfermagem). It is the oldest Brazilian nursing journal and its mission is to disseminate scientific production in the different areas of health that are of interest to nursing, including those that express the Association’s political project.
Its first title was "Annaes de Enfermagem", from May 1932 to April 1941, modified to "Anais de Enfermagem", from January 1946 until December 1954, when it started having the current title – Brazilian Journal of Nursing (Revista Brasileira de Enfermagem – REBEn). In its trajectory, it had a single interruption, in the period from May 1941 to December 1945.
The REBEn is published in electronic format, bimonthly, with open access. The print version was discontinued.
Its abbreviated title is Rev Bras Enferm, which should be used in bibliographies, footnotes and bibliographical references and subtitles.
Open Access Policy - Revista Brasileira de Enfermagem is published under the Open Access model and is therefore free for anybody to read and download, and to copy and disseminate for educational purposes.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type CC-BY.
The Revista Brasileira de Enfermagem adopted until Jun/2015 the Creative Commons license attribution-type BY-NC. Currently the license is the attribution-type BY.
The journal is financially supported by:
EDITOR IN CHIEF
1. EDITORIAL POLICY
REBEn is a peer-reviewed open access journal that has the mission of disseminating nursing and health sciences.
REBEn accepts manuscripts in Portuguese, English, and Spanish. It is published only in electronic and streaming. Content published on REBEn is under license from Creative Commons (CC-BY) Attribution 4.0 International.
Upon acceptance, manuscripts written in Portuguese or Spanish must be translated into English.
Manuscripts should be intended exclusively for REBEn, and their simultaneous submission to another journal(s) is not permitted.
REBEn has a consolidated digital preservation policy together with SciELO.
REBEn endorses open science practices consisting of transparent and accessible knowledge that is shared and developed through collaborative work networks (FOSTER Open Science Definition).
Given this definition and aiming to increase the rigor, responsibility and reproducibility of research in favor of transparency, quality, and speed, according to the TOP (Transparency and Openness Promotion) recommendations, REBEn accepts manuscripts from preprint servers for peer review process.
1.1 Declaration on Ethics and Integrity in Research
REBEn supports the recommendations for conducting, reporting, editting, and publishing scholarly work in medical journals (Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals) of the International Committee of Medical Journal Editors (International Committee of Medical Journal Editors). These recommendations, relating to integrity and ethical standards in conduct and research reporting, are available at URL http://www.icmje.org/urm_main.html.
1.2 Cases that require corrections, retractions and editorial expressions of concern
REBEn adopts the recommendations of the codes of ethical conduct in publication of the Committee on Publication Ethics (COPE).
It also adopts the Ithenticate system for similarity identification. Practices that harm scientific integrity, such as plagiarism, self-plagiarism, data fabrication, redundant publication and undisclosed conflicts of interest, can be identified during the review process or even after publication.
Once identified, they will be taken for evaluation by members of the Editorial Board and will follow the flowchart provided by COPE so that a proper decision can be taken, such as: embargo, suspension of publishing in the journal for a period determined by the Editorial Board, publication of a letter of concern or retraction of the published manuscript, highlighting the reason(s) for retraction.
Authors will be immediately informed of all stages of this process, as well as the final decision.
REBEn encourages the submission of letters to the editor, where readers can present their criticisms and/or request clarification of any doubts raised by an article recently published in the journal.
1.3 Conflict of Interest
REBEn requires that all authors of the manuscript declare any potential sources of conflicts of interest. Any interest or relationship, financial or otherwise, or personal, religious or political beliefs that may be perceived as influencing an author’s objectivity are considered a potential source of conflict of interest. Potential sources of conflict of interest include, but are not limited to: patent or ownership of shares, membership in a company’s board of directors, membership in a company’s advisory board or committee, and consulting or receiving a speaker’s fee. company. The existence of a conflict of interest does not prevent publication. If the authors have no conflict of interest to declare, they must declare it when submitting the manuscript in the Letter to the Editor. It is the responsibility of the corresponding author to review this policy with all the authors, and collectively disclose with the submission ALL the commercial and other pertinent relationships.
The conflict of interest declaration must be informed at the time of submission of the manuscript by the ScholarOne system
1.4 Aprovall of the Research Ethics Council for studies involving humans or animals
REBEn considers condition sine qua non for publication that the submitted manuscripts have complied with the ethical-legal guidelines that involve the elaboration of academic and/or technical-scientific works and research with humans or animals.
In the case of research involving human beings, and in compliance with CNS Resolution 466/2012 the Brazilian author (s) must mention in the manuscript the approval of the project by the Ethics Committee recognized by the Brazilian National Research Ethics Committee of the Brazilian National Health Council (CONEP (Comissão Nacional de Ética em Pesquisa)-CNS (Conselho Nacional de Saúde)), or by an equivalent body, when the research has been carried out in another country.
In experimental research involving animals, Law 11,794,of October 8, 2008, which regulates item VII of paragraph 1 of Article 225 of the Federal Constitution, establishing procedures for the scientific use of animals, and the rules established in Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, National Academy of Sciences, Washington, DC, USA), 1996, and the Ethical Principles in Animal Experimentation of the Brazilian College of Animal Experimentation (COBEA - Colégio Brasileiro de Experimentação Animal), 1991. This information must be included in the method according to the ARRIVE recommendation.
In the METHODS section, indicate whether the research that gave rise to your manuscript was submitted for consideration by the Research Ethics Committee in your country, or provide the justification in case of exemption in the following form:
“The study was conducted in accordance with national and international ethics guidelines and approved by the Research Ethics Council or Committee of [INSTITUTION NAME], whose opinion is attached to this submission. OR “Ethical review and approval was waived for this study, due to REASON (please provide a detailed rationale).”
Declaration of Informed Consent:
Any research article describing a study involving human subjects must contain this statement under METHODS.
“Informed consent was obtained from all subjects involved in the study through [WRITTEN, ONLINE; BETWEEN OTHERS]". OR “Patient consent was waived for REASON (please provide detailed justification).” OR “Not applicable” for studies that do not involve humans.
If deemed necessary, editors may request further information.
1.5 Use of Artificial Intelligence:
Authors should disclose in their manuscript the use of AI and AI-assisted technologies in the writing process by following the instructions below. A statement will appear on the published work. Please note that the authors are responsible for the content of the work.
Authors must disclose the use of generative AI and AI-assisted technologies in the writing process by adding a statement under the METHODS of their manuscript in the main manuscript file. The statement should be placed in a new section titled 'Statement of Generative AI and AI-Assisted Technologies in the Writing Process'.
Disclaimer: During the preparation of this work, the author(s) used [TOOL/SERVICE NAME] for [REASON]. After using this tool/service, the author(s) have revised and edited the content as necessary and have taken full responsibility for the content of the post.
This statement does not apply to the use of basic tools for checking grammar, spelling, references, etc. If there is nothing to disclose, there is no need to add a declaration.
2. MANUSCRIPT CATEGORIES
REBEn considers for publication only articles that meet the quality standards established by the guidelines for health research production - Enhancing the Quality and Transparency of Health Research Network (EQUATOR). It is mandatory to indicate in the study design method which Equator instrument was used to guide the research (https://www.equator-network.org/toolkits/selecting-the-appropriate-reporting-guideline/, https://clinical-trials.ai, https://doi.org/10.1136/bmj.m3164,https://doi.org/10.1136/bmj.m3210, https://doi.org/10.1136/bmj.m3505 and systematic reviews must follow the guidelines updated in the PRISMA guideline. Failure to comply with this rule will lead to the manuscript being archived.
 Liu X, Rivera S C, Moher D, Calvert M J, Denniston A K. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension BMJ 2020; 370 :m3164. https://doi.org/10.1136/bmj.m3164
 Rivera S C, Liu X, Chan A, Denniston A K, Calvert M J. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension BMJ 2020; 370 :m3210. https://doi.org/10.1136/bmj.m3210
 Wynants L, Smits L J M, Van Calster B. Demystifying AI in healthcare BMJ 2020; 370 :m3505. https://doi.org/10.1136/bmj.m3505
 Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372(71). https://doi.org/10.1136/bmj.n71
Types of articles considered:
Manuscript Categories - Checklist
2.1 Record of Clinical Studies, Systematic Reviews and other Reviews
2.2 Research Data
REBEn encourages the deposit and sharing of research data that support the publication of the article. Research data refers to the results of observations or experiments that validate the research results. To enable data reproducibility and reuse, REBEn recommends that starting in 2021 and mandatory starting in 2022, the deposit and sharing of the research project, partial research reports, software, codes, models, algorithms, protocols, procedures information, workflow methodologies, field notebooks, diaries, questionnaires, audio or video tapes, methods and other useful materials related to the project in a public data repository.
Data Repository is a database where digital content and resources are stored that can be searched and retrieved for later use. There is a variety of Brazilian repositories in which it is possible to deposit research data. An example is SCIELO Data. The universities of the state of São Paulo (USP, UNIFESP, UNICAMP. ITA, among others) have developed a metasearch engine in which it is possible to perform a search in a diversity of data repositories: https://metabuscador.uspdigital.usp.br/. To find the most appropriate repository, as well as information on how to deposit, share and use research data and other relevant materials, see: https://www.re3data.org/ and https://fairsharing.org.
For manuscript authors who are sharing their data, REBEn encourages to cite and link them in the manuscript, in the chapter AVAILABILITY OF DATA AND MATERIAL, AFTER THE CONCLUSION OR FINAL CONSIDERATIONS AND BEFORE the References section.
2.3 Preprint publication acceptance
REBEn accepts manuscripts that were previously deposited on a non-commercial preprint server, as long as they have not been subjected to peer review in another journal simultaneously.
The author responsible for the submission must inform whether the manuscript is deposited in a preprint server and must provide the corresponding DOI. The manuscript must obey a license that allows sharing the material in any medium or format (Creative Commons - CC-BY).
REBEn recommends filling out the Open Science Compliance Form, which must be submitted as a supplementary file to the manuscript and which will be accessible to reviewers.
2.4 Authorship Responsibilities
Authorship confers credit and has important academic, social and financial implications. Authorship implies responsibility for the published work. For all authors who have made intellectual and substantial contributions to the manuscript, REBEn requires that each author specify their contributions to the work. The corresponding author or author who sent the work will indicate, during the submission process, the guarantee and accuracy of the integrity of all data reported in the manuscript (Declaration Model – forward as supplementary file).
All collaborators who do not meet the criteria for authorship should be listed in the Acknowledgments section, as well as financial support from funding agencies.
For manuscripts previously published on preprints servers, it is advisable to keep the same authors, based on the criteria already described.
1 Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
3. MANUSCRIPT PREPARATION
The manuscripts will only be accepted for assessment if they are strictly in accordance with the model available in the Templates and prepared as follows:
Microsoft Office Word file, with mandatory configuration of pages on A4 paper (210x297mm) and 2 cm margins on all sides, Times New Roman font size 12, 1.5 spacing between lines, paragraphs with 1.25 indentation cm.
3.1 Title Page (Template 1)
3. 2 Text structure
Abbreviations should not be used in the title and subtitles of the manuscript and in the abstract. For tables and figures with abbreviations, it is mandatory to insert a footnote to the table or figure. In the text, use only standard abbreviations. In the first citation, the abbreviation is shown in parentheses after the full term.
3.3 Main Document (Template 2)
The main document, without identifying the authors, must contain:
Avoid citations of theses, dissertations, books and chapters, newspapers or non-scientific magazines (Magazines) and in press, except when dealing with a theoretical framework (E.g., Handbook Cochrane).
REBEn encourages using DOI, as it guarantees a permanent link to the electronic article. For articles or texts published on the internet that do not contain a DOI, indicate the address of the complete URL as well as the access date on which it was consulted.
Up to 3 preprint references (optional) will be accepted.
Suggestion: REBEn accepts preprint references as long as it is extremely necessary. We strongly suggest that during the peer review process and press release, the authors verify that the version cited has already been published and update it with the reference of the corresponding journal.
Most common examples of references:
Articles with DOI identifier:
Articles in another language
Book on Internet
On figshare: Plessis- Faurie, Alida S. Mother and Preterm Infant in the South African Informal Settlement [Internet]. Visualize Your Thesis. Presentation; 2019 [cited 2020 Nov 13]. Video: 1 min 13 sec. Available from: https://figshare.com/articles/presentation/A_Mother_and_Preterm_Infant_in_a_South_African_Informal_Settlement/9992606 doi : https://doi.org/10.6084/m9.figshare.9992606.v1
Research data: Coin L. Genomics of development and disease [dataset]. 2014 Jun 1 [cited 2017 Jun 9]. The University of Queensland. Available from: https://doi.org/10.14264/uql.2016.583.
Repository Data: Global Health Observatory Data Repository [Internet]. Geneva: WHO. [cited 2019 Jul 3]. Available from: http://www.who.int/gho/database/en/ .
Data deposited in Repositories: Zimmermann B, Tkalčec Z, Mešić A, Kohler A. Characterizing aeroallergens by infrared spectroscopy of fungal spores and pollen [dataset]. 2015 Apr 27 [cited 2019 Jul 3]. Dryad Digital Repository. Available from: https://datadryad.org/resource/doi:10.5061/dryad.f4v0s. Referenced in doi: doi.org/10.1371/journal.pone.0124240.
Data described in articles: Mann C, Kane L, Dai M, Jacobson K. Description of the 2012 NEMSIS public-release research dataset. Prehosp Emerg Care. 2015;19(2):232-40. https://doi.org/10.3109/10903127.2014.959219.
4. MANUSCRIPT SUBMISSION PROCESS
Manuscripts must be submitted to REBEn through the URL http://www.scielo.br/reben/, accessing the Online Submission link.
To initiate the process, the person responsible for submission must first register in the system as an author. The system is self-explanatory and, upon completion of the process, an ID will be generated for the manuscript, with a number code (E.g., REBEn 2020-0001).
The person responsible for the submission will receive a message stating the URL of the manuscript and a login so that he or she can follow, in the system administration interface, the progress of the document in the stages of the editorial process.
Only manuscripts that are formatted in the submission template will be checked by the editorial office for compliance with the rules. Before submitting the manuscript, authors should check REBEn rules, strictly follow the CHECKLIST and have all the necessary documents for submission. It is mandatory to complete the metadata in the submission form.
Each document must be attached, separately, in the field indicated by the system.
To start the process, the person responsible for the submission must previously register in the system as an author creating/associating the ORCID (Open Researcher and Contributor ID) register. All authors must have their registration associated with ORCID updated.
Authors must nominate four possible referees to assess the manuscript. These nominees must be doctors, have no conflict of interest and do not belong to any of the authors’ institutions. The referees can be accepted or not by the associated editors. Possible reviewers can be tracked on the lattes platform according to the theme of the manuscript.
Manuscripts that do not meet the standards in the second round of the checklist will be filed without an compliance rate refund.
5. MANUSCRIPT ASSESSMENT PROCESS
REBEn adopts, for approved manuscripts that have not been made available on preprint servers, the double-blind review, which consists of two or more arbitrators designated to carry out the review of the manuscript. For manuscripts previously published on preprint servers, REBEn understands that it is not possible to guarantee the anonymity of the authors, being guaranteed only by the reviewers involved in the process. For both cases, the name of the Associate Editor (AE) involved with the peer review process is published along with the manuscript.
In order to make the peer review process more transparent and supported by the precepts of open science, from 2021 onwards, REBEn will adopt the transparent peer review process (Figure 1), which consists of sharing the review report issued by the reviewers but without identifying them. As of 2022, REBEn will offer authors and reviewers the option to choose to display reviewers’ reports (and authors’ responses) along with the published article.The peer review content will only appear when everyone accepts it. Reviewers can also sign their report if they wish.
Figure 1 - Transparent/Open and Blind Peer Review Concept
5.1 Editorial Decision and Review
All articles published on REBEn go through the peer review process and receive at least two reviews. The Editor-in-Chief will make and communicate the decision, which will be one of the following:
Reject & Resubmit
Reject after peer review
In all decisions that allow for a new round or resubmission, all comments from reviewers and editors must be answered point-by-point in an objective and literature-supported manner.
Reject immediately (before peer review)
5.2 Author Resources
Authors can appeal an editorial decision by sending an email to the REBEn Editorial Office, provided that the text has passed at least one round of peer review. That is, it is not possible to appeal the decision Reject immediately.
The resource must provide a detailed rationale, including point-by-point responses to comments from reviewers and/or the Editor. The journal's Editor-in-Chief will forward the manuscript and related information (including reviewer identities) to an Associate Editor and a member of the Editorial Board for deliberation. They will be asked to provide an advisory recommendation on the manuscript and will be able to recommend acceptance, further peer review or maintain the original rejection decision. A rejection decision at this stage is final and cannot be reversed.
6. PORTUGUESE PROFFREADING AND TRANSLATION OF MANUSCRIPTS
When the article is accepted, the author will receive an email from the editorial office with instructions on:
The return of the manuscript in translated, proofread and certified versions, as well as proof of payment of the publication fee with the payer’s name and visible payment date, must be sent to the email email@example.com within up to 25 calendar days. This missed period and non-compliance with the model (Final Template sent by the office), will cause the manuscript to be archived.
Kindly carefully check the submission of the manuscript according to the final template (name of authors, ORCID institution, order of authorship). The Editorial Board decided to charge R$ 200.00 (two hundred reais) in case of erroneous due to the authors’ carelessness.
7. COMPLIANCE AND EDITING FEES
*compliance with the journal rules
Method of payment: Exclusively by Pagseguro or Paypal (http://reben.com.br/revista/).
FOR INSTITUTIONAL PAYMENTS, CONTACT: firstname.lastname@example.org
The compliance rate will not be refunded if the manuscript is not accepted for publication.
Doubts about the rules, submission and resubmission will be answered exclusively by email CONTACT US (FALE CONOSCO) (email@example.com).
Prior to the use of CONTACT US (FALE CONOSCO) carefully review the rules above. Only questions not covered in the Instructions to Authors will be answered.
At the beginning of the submission of the manuscript the author is aware and in compliance with the journal rules.